MedTrace Logo

Renal Denervation for Treatment of Resistant Hypertension in Patients With Chronic Kidney Disease

NCT01747382 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2017-05-02

No results posted yet for this study

Summary

Recent clinical studies have demonstrated that catheter-based renal sympathetic nerve ablation is safe and effective in treating patients with resistant hypertension. However, there is limited data on its safety and efficacy in patients with Chronic Kidney Disease.

The investigators hypothesize that catheter-based renal sympathetic nerve ablation is safe and effective in the treatment of resistant hypertension in patients with Chronic Kidney Disease.

Conditions

Interventions

PROCEDURE

Renal denervation

Sponsors & Collaborators

  • National Heart Centre Singapore

    collaborator OTHER

  • Singapore General Hospital

    lead OTHER

Principal Investigators

  • Chieh Suai Tan, M.B.B.S · Singapore General Hospital

  • Soo Teik Lim, M.B.B.S · National Heart Centre of Singapore

Eligibility

Min Age
21 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-04-30
Primary Completion
2015-09-30
Completion
2017-09-30

Countries

  • Singapore

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01747382 on ClinicalTrials.gov